Skip to main content
OpenTrials
Completed

NCT Number: NCT03665688

Comparing Outpatient to Inpatient Cervical Ripening Using Dilapan-S®

The target population for our study is women who present for induction of labor. If there is a decision by the obstetrical team to place a mechanical dilator for cervical ripening, the obstetrical team will notify the research staff so that the patient may be screened for the study. If the subject is eligible for the trial, written informed consent will be obtained by person-to-person contact. The PI, study coordinator, or a collaborator will be responsible for the informed consent procedure. After informed consent is obtained and Dilapan-S is placed, the patient will be randomized to the Outpatient or the Inpatient group.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Columbia University Irving Medical Center, New York, United States

Loading trial locations.

About this study

Group Assigned to Outpatient Cervical Ripening After Dilapan-S® placement, subject will be monitored for at least 30 minutes. If no contraindications, such as tachysystole, active vaginal bleeding, rupture of membranes or nonreassuring fetal testing (defined as minimal or absent variability, abnormal baseline, or presence of decelerations) evidence of labor, or other serious medical conditions deemed by the clinical staff or the attending physician to preclude outpatient cervical ripening develop after insertion, the subjects will be randomized. After randomization subject will record the pain she experienced during insertion in the patient's survey (see Appendix 3). Those subjects randomized to outpatient ripening will be given the option to either return home or to stay in a hotel if transportation is an issue. The cost for the hotel will be covered by the study budget. Subjects will be allowed to ambulate, shower and perform regular activity during that period. "Nothing per vagina" will be allowed (incl. intercourse, tampons etc.).

Group Assigned to Inpatient Cervical Ripening Subjects randomized to inpatient management will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain "nothing per os" (NPO), "nothing per vagina" and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated.

Labor Induction and Labor Management of the subject after the initial 12 hours of pre-induction or following the earlier removal or spontaneous expulsion of the dilator will be the same for both groups and at the discretion of the clinical team. Additional ripening (mechanical or prostaglandins) and/or oxytocin may or may not be needed. If needed, duration, type and dose of additional ripening agents and oxytocin will be documented.

Routine intrapartum care will be provided and relevant data collected by the subject's managing obstetrical team.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant woman whose plan of care is induction of labor
  • Maternal age between 18 and 45 years
  • Understanding and capable to sign informed consent
  • Singleton pregnancy
  • Gestational age ≥ 37 0/7 weeks (based on a sure last menstrual period or a first trimester dating ultrasound)
  • Live fetus in cephalic presentation
  • Intact membranes
  • Pelvic exam (sterile vaginal exam) of less than or equal to 3cm and at most 60% effaced

Exclusion criteria

  • Active labor
  • Active genital herpes
  • Chorioamnionitis
  • Transfundal uterine or cervical surgery
  • Previous cesarean delivery
  • Non-reassuring fetal status
  • Need for continuous maternal or fetal monitoring during ripening
  • Contraindication for vaginal delivery
  • Active vaginal bleeding
  • Abnormal placental location or adherence (placenta previa or unresolved low lying placenta)
  • Estimated fetal weight > 5000 g (non diabetic) or > 4500 g (diabetic)
  • Intrauterine growth restriction (estimated fetal weight <10 percentile)
  • Oligohydramnios (amniotic fluid index < 5cm or deep vertical pocket of < 2 cm)
  • Fetal anomaly
  • Need for inpatient care (e.g. hypertension, insulin-dependent diabetes)
  • Poor or no access to a telephone and cannot be placed in the hotel
  • Absence of support person ( no adult accompanying the subject during outpatient cervical ripening period)

Treatment and study plan

Outpatient Dilapan-S

Device

After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L&D unit for standard protocol of labor induction.

Other names: Outpatient cervical ripening with Dilapan-S

Inpatient Dilapan-S

Device

After Dilapan-S placement, subjects will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain "nothing per os" (NPO), "nothing per vagina" and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated.

Other names: Inpatient cervical ripening with Dilapan-S

Primary outcomes

  1. Number of Participants With Hospital Stay Longer Than 48 Hours

    Time frame: 72 hours or discharge home time, whichever occurs first

    Rate of hospital stay longer than 48 hours (from admission to discharge)

Secondary outcomes

  1. Number of Participants With Vaginal Deliveries 2-4 Days

    Time frame: 2-4 days

    Rate of vaginal deliveries (%)

  2. Number of Participants With Vaginal Deliveries - 24 Hours

    Time frame: 24 hours

    Rate of vaginal deliveries within 24 hours since admission to hospital (%)

  3. Time From Hospital Admission to Active Stage of Labor

    Time frame: 1-2 days

    Time from hospital admission to reach active stage of labor defined as cervical dilation of ≥ 6 cm (in minutes)

  4. Change in Bishop Score From Insertion of Device to Extraction

    Time frame: 12 hours

    Change in Bishop score (based on cervical dilation, position of cervix, effacement of cervix, fetal station and softness of cervix) . Calculated as Bishop score value at 12 hours minus value at baseline. Bishop score ranges from zero to 13, with zero meaning you're not ready for induction and 13 indicating a better chance for successful induction. A higher score means that labor is closer, and that induction has a good chance of being successful.

  5. Number of Participants With Operative Vaginal Delivery

    Time frame: 1-4 days

    Rate of operative vaginal deliveries (%)

  6. Number of Participants With Cesarean Delivery

    Time frame: 1-4 days

    Rate of caesarean deliveries (%)

Sponsors and collaborators

Lead sponsor

The University of Texas Medical Branch, Galveston

Other

Collaborators

  • Medicem International CR s.r.o.

Registry information

Official study title

Induction of Labor in Women With Unfavorable Cervix: Randomized Controlled Trial Comparing Outpatient to Inpatient Cervical Ripening Using Dilapan-S® (HOMECARE)

Acronym: HOMECARE

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Sep 11, 2018
Registry last updated
Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.